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Abstract
Background:  In this study, we analyzed maximal inspiratory pressure (MIP) and maximal
expiratory pressure (MEP) values in a stable COPD population compared with normal subjects.
We evaluated the possible correlation between functional maximal respiratory static pressures and
functional and anthropometric parameters at different stages of COPD. Furthermore, we
considered the possible correlation between airway obstruction and MIP and MEP values.
Subject and methods: 110 patients with stable COPD and 21 age-matched healthy subjects
were enrolled in this study. Patients were subdivided according to GOLD guidelines: 31 mild, 39
moderate and 28 severe.
Results: Both MIP and MEP were lower in patients with severe airway impairment than in normal
subjects. Moreover, we found a correlation between respiratory muscle function and some
functional and anthropometric parameters: FEV1 (forced expiratory volume in one second), FVC
(forced vital capacity), PEF (peak expiratory flow), TLC (total lung capacity) and height. MIP and
MEP values were lower in patients with severe impairment than in patients with a slight reduction
of FEV1.
Conclusion: The measurement of MIP and MEP indicates the state of respiratory muscles, thus
providing clinicians with a further and helpful tool in monitoring the evolution of COPD.
Background
In several diseases, the evaluation of respiratory muscle
strength can prove to be very useful. The measurement of
the maximum static mouth pressures made against an
occluded airway (maximal expiratory pressure and maxi-
mal inspiratory pressure) is the most widely used and is a
simple way to gauge respiratory muscle strength and to
quantify its severity [1-3].
When we analyze maximal respiratory pressure, we
should consider both the difficulty that some subjects
have in performing a maximal effort and the normal bio-
logical variability of respiratory muscle strength [4].
Maximal inspiratory pressure (MIP) is the maximum neg-
ative pressure that can be generated from one inspiratory
effort starting from functional residual capacity (FRC) or
residual volume (RV) [5,6]. Maximal expiratory pressure
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(MEP) measures the maximum positive pressure that can
be generated from one expiratory effort starting from total
lung capacity (TLC) or FRC. Unlike inspiratory muscles,
expiratory muscles (abdominal and thoracic muscles)
reach their optimal force-length relationship at elevate
pulmonary volumes [7].
During normal breathing, most of the respiratory work
depends on the diaphragm function and the accessory res-
piratory muscles become necessary only during deep
inspiration [8].
The mouth pressures recorded during these maneuvers are
assumed to reflect respiratory muscle strength [9].
It is known that a reduction of MIP and MEP has been
associated with several neuromuscular diseases, but it is
also possible to point up lower values in patients with
chronic obstructive pulmonary disease (COPD) [10-12].
The factors contributing to respiratory muscle weakness in
many patients with COPD are: a) malnutrition related to
biochemical, anatomical and physiological changes; b)
muscular atrophy; c) steroid-induced myopathy; d) pul-
monary hyperinflation with increased residual volume; e)
reduced blood flow to the respiratory muscles [13-19].
The measurement of MIP and MEP is indicated in any of
these situations or when dyspnea or hypercapnia are not
proportional to FEV1 reduction [6].
Age and sex could influence MIP and MEP values; these
are lower in females than in males and quite constant
until seventy years of age when they start to decrease [6].
The objectives of this study were: (1) to describe MIP and
MEP values in a stable COPD population, (2) to explore
the effect of varying degrees of obstructive ventilatory
impairment on MIP and MEP measurement, (3) to evalu-
ate the possible correlation between functional maximal
respiratory pressures and functional parameters at differ-
ent stages of COPD.
Methods
During 1 year 110 patients suffering from COPD were
enrolled in this study. All patients were in a clinically sta-
ble condition and the mean age was 70 ± 8 years (Table
1).
At the first examination, we excluded those patients
whose FEV1 improvement, after a bronchodilatory test,
was ≥ 12% and 200 mL of the baseline value and with a
history of asthma. Other patients, with clinically signifi-
cant diseases such as fibrothorax, bronchiectasis, tubercu-
losis or neuromuscular diseases were also excluded. Some
patients were excluded because of lack of compliance dur-
ing the forced expiratory test or during the MIP and MEP
maneuvers.
All patients gave their written informed consent before the
study and the Ethics Committee approved the protocol.
At the enrolment, all the subjects were examined. Anthro-
pometric measurements (age, height and weight) were
taken and pulmonary function tests, including flow/vol-
ume spirometry and N2 Washout, were conducted. Maxi-
mal static inspiratory and expiratory mouth pressures
were measured using a portable mouth pressure meter
(Spirovis – COSMED – Pavona – Italy); this had a dispos-
Table 1: Characteristics of patients
CONTROL GROUP MILD MODERATE SEVERE p VALUE* COPD PATIENTS
N° 21 31 39 28 98
Age 67 ± 5 67 ± 8 71 ± 6 72 ± 7 p > 0.05 70 ± 8
Body weight (Kg) 72 ± 6 76 ± 11 78 ± 12 75 ± 20 p > 0.05 77 ± 15
Body height (cm) 165 ± 8 168 ± 9 166 ± 8 167 ± 6 p > 0.05 167 ± 8
MIP (cmH2O) 99 ± 18 84 ± 22 80 ± 34 65 ± 20 p = 0.0002 77 ± 28
MEP (cmH2O) 102 ± 26 93 ± 29 90 ± 32 75 ± 21 p = 0.01 89 ± 31
FEV1 (L) 2.7 ± 0,5 2.4 ± 0,6 1.5 ± 0.4 0.9 ± 6.3 p < 0.0001 1.7 ± 0.7
FEV1 % 102 ± 12 91 ± 11 65 ± 8 38 ± 7 p < 0.0001 65 ± 22
FVC (L) 3.3 ± 0.9 3.2 ± 0.8 2.4 ± 0.7 1.9 ± 0.6 p < 0.0001 2.5 ± 0.9
FVC % 101 ± 12 96 ± 9 76 ± 10 59 ± 14 p < 0.001 77 ± 18
PEF (L/sec) 6.5 ± 2 6.6 ± 1.6 4.9 ± 1.7 3.1 ± 1.2 p < 0.0001 4.9 ± 2
PEF % 102 ± 12 91 ± 15 71 ± 18 45 ± 15 p < 0.0001 70 ± 24
TLC (L) 4.9 ± 1.3 5.9 ± 1.1 5.4 ± 1.3 5.6 ± 1.4 p = 0.037 5.7 ± 1.3
TLC % 98 ± 20 98 ± 13 94 ± 14 97 ± 18 p = 0.0007 97 ± 16
RV (L) 2 ± 0.5 2.5 ± 0.7 3 ± 0.8 3.9 ± 1.2 p < 0.0001 3 ± 1
RV % 97 ± 20 111 ± 29 124 ± 32 151 ± 47 p < 0.0001 128 ± 39
RV/TLC % 40 ± 20 41 ± 11 50 ± 20 66 ± 23 p < 0.0001 49.7 ± 19
*Comparison between the four groups (control, mild, moderate, severe) have been made by analysis of variance (ANOVA).Respiratory Research 2008, 9:8 http://respiratory-research.com/content/9/1/8
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able mouthpiece, and a small leak to prevent glottic clo-
sure. MIP was obtained at the level of RV and MEP was
measured at the level of TLC. The measurements were
made in standing position. The subjects were verbally
encouraged to achieve maximal strength. The measure-
ments were repeated until five values varying by less than
5% and sustained for at least 1 s were obtained; the best
value achieved was considered in the data analysis.
Forced expiratory tests were recorded with a Cosmed
Quark spirometer (PFT4 SUITE – COSMED – Pavona –
Italy) which was calibrated each morning using the same
3 L precision syringe.
We divided patients into three groups on the basis of air-
way obstruction: mild (FEV1 > 80%), moderate (FEV1
between 80 and 50%), and severe (FEV1 < 50%) with
FEV1/FVC ratio <70% in all the groups.
The control group included 21 age-matched normal sub-
jects who were non-smokers, free of respiratory symptoms
and disease and with normal functional parameters
(Table 1).
Statistical analysis was performed for all measured func-
tional parameters using GraphPad Prism version 4.00 for
Windows (GraphPad Software, San Diego California
USA). Standards descriptive statistics based on mean and
standard deviation (SD) for quantitative variables were
used. The mean difference between MIP/MEP in healthy
subjects and MIP/MEP in patients with COPD was deter-
mined by the unpaired Student's t test. Statistical differ-
ences for respiratory muscle strength and different stage of
COPD were analyzed by analysis of variance (ANOVA).
The Pearson's test was performed to assess possible corre-
lation between MIP and MEP values and anthropometric
and functional parameters.
All p values were two sided and values below 0.05 were
considered statistically significant.
Results
During this study, 12 COPD patients were withdrawn: 5
because of a contemporary restrictive deficit and 7
because of their insufficient compliance during the forced
expiratory test or during the MIP and MEP maneuvers.
Therefore, 98 patients took part in this study. Table 1
shows the anthropometric parameters and lung function
of the patients studied.
The MIP and MEP values of healthy subjects were used as
a control group for the comparison with patients with dif-
ferent stages of COPD.
MEP was significantly lower (p = 0.0014) in patients with
severe airway obstruction than in the control group; no
differences were observed in mild and moderate patients
(p > 0.05).
At the same time, MIP was significantly lower at all the
stages of COPD than in the control group: mild p = 0.010;
moderate p = 0.018; severe p < 0.0001.
Statistical analysis performed on the total of COPD
patients to assess the possible correlation between MIP
and MEP values and anthropometric and functional
parameters showed significant (p < 0.05) positive correla-
tions among maximal static inspiratory pressure and FEV1
(L, r2 = 0.13, Figure 1), FVC (L, r2 = 0.20), PEF (L/sec, r2 =
0.19), TLC (L, r2 = 0.11) and height (r2 = 0.09).
Similar results were showed between MEP and the same
functional and anthropometric parameters (FEV1 r2 =
0.13, figure 2; FVC r2 = 0.19; PEF r2 = 0.22; TLC r2 = 0.12;
height r2 = 0.15).
Respiratory muscle strength, however, had no significant
correlation with RV and RV/TLC (Figures 3, 4, 5, 6),
weight and age.
Moreover, we evaluated whether there was a possible cor-
relation between COPD stage and respiratory muscular
strength. The analysis of variance (ANOVA) showed no
statistically significant difference between mild and mod-
erate patients (p > 0.005), while the difference between
mild and severe was significant as well as that between
moderate and severe patients.
Relationship between MIP and FEV1 (p = 0.0002; r2 = 0.13) Figure 1
Relationship between MIP and FEV1 (p = 0.0002; r2 = 0.13).Respiratory Research 2008, 9:8 http://respiratory-research.com/content/9/1/8
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Discussion
To our knowledge, this is the first study that analyzes MIP
and MEP variation in the different stages of COPD severity
to understand when MIP and MEP start to decrease.
The main finding of this work is that airway obstruction
may be closely associated with decreased respiratory pres-
sures in patients with COPD. In fact, both MIP and MEP
values were lower in patients with severe obstruction com-
pared with healthy subjects. MIP decreased also in patient
with mild and moderate functional impairment: this
could suggest an earlier deterioration of the inspiratory
muscles in this sort of patients.
Similar results have been showed in a recent work that
limited the evaluations only to the inspiratory muscle
strength [20].
Dynamic functional parameters are a measure of the res-
piratory muscular strength as well as maximal respiratory
pressures. In fact with the reduction of FEV1, PEF and FVC,
as in severe COPD, we have observed a similar decrease in
MIP and MEP. Interestingly, our study highlights the
importance of the predictivity of functional parameters
(FEV1, PEF, FVC, and TLC) on MIP and MEP reduction in
COPD patients.
Relationship between MIP and RV/TLC (p > 0.05; r2 = 0.01) Figure 5
Relationship between MIP and RV/TLC (p > 0.05; r2 = 0.01).
Relationship between MIP and RV (p > 0.05; r2 = 0.01) Figure 3
Relationship between MIP and RV (p > 0.05; r2 = 0.01).
Relationship between MEP and FEV1 (p = 0.0002; r2 = 0.13) Figure 2
Relationship between MEP and FEV1 (p = 0.0002; r2 = 0.13).
Relationship between MEP and RV (p > 0.05; r2 = 0.0009) Figure 4
Relationship between MEP and RV (p > 0.05; r2 = 0.0009).Respiratory Research 2008, 9:8 http://respiratory-research.com/content/9/1/8
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Nishimura and colleagues showed a similar relation
between respiratory muscle force and FEV1 [18].
Our findings could be explained by several factors.
Patients with severe disease probably have a decrease in
tension produced by inspiratory muscle shortening. How-
ever, our study did not show a correlation between maxi-
mal respiratory pressure and residual volume at any of the
different stages even though air-trapping was different
among patients.
As reported by Rochester, chronic airflow limitation per-
manently shortens the diaphragm, in this way muscles
lose sarcomeres, but the length of individual sarcomeres is
restored to normal and the force-length relationship of
the shortened diaphragm is reset to a new and shorter
muscle length so, the relation of diaphragm length to lung
volume is the same as in normal subjects [12].
Further support for the concept that COPD does not per-
manently alter diaphragm muscle length in human COPD
comes from another study by the same author who
reported that the diaphragm undergoes an adaptation to
compensate for the mechanical stresses that pulmonary
hyperinflation places on it [21].
Similarly, Nishimura and colleagues showed no signifi-
cant correlation between respiratory muscular strength
and RV [18].
Similowsky et al. demonstrated that the diaphragm of
COPD patients undergoes some structural adaptation
which preserves or even increases its capacity to generate
pressure even if the muscular function is impaired because
of an alteration in chest wall geometry [22,23].
Walsh and coworkers found that the size of the rib cage
and the arrangement of the ribs where not different
between severely hyperinflated patients with COPD and
healthy subjects [24].
McKenzie et al observed that at resting functional residual
capacity the curvature of the diaphragm is only 3.5%
smaller in patients with severe COPD than in healthy sub-
jects [25].
Additional mechanisms of muscular impairment in
COPD may include malnutrition, which predisposes the
diaphragm to a greater loss in muscle mass in proportion
to a patient's body-weight reduction [26-30]. Prolonged
malnutrition can lead to skeletal and respiratory muscle
wasting with severe effects on the contractile and fatigue
properties of the diaphragm [26-30]. This suggests that a
nutritional supplementation should be a primary inter-
vention in patients with lean body mass [31].
Corticosteroids, routinely used to manage chronic inflam-
mation, have negative consequences, including steroid
myopathy of respiratory and skeletal muscles, even at low
doses [26-28].
Further, electrolyte imbalance and hypoxemia alter mus-
cle function and should be corrected, when possible
[26,27].
Oxidative stress, disuse, and systemic inflammation may
contribute to the observed muscle abnormalities and each
factor has its own potential for innovative treatment
approaches [26,27].
These processes contribute to the reduced capacity of the
respiratory muscles in COPD and translate to measurable
decreases in maximal pressure generation, exhibited as
lower values for maximal inspiratory pressure (MIP),
maximal expiratory pressure (MEP), sniff testing, maxi-
mal voluntary ventilation (MVV), and exercise tolerance.
There is also a strength correlation between thoracic mor-
phology dimension and anthropometric variables even if
some studies have obtained conflicting results with age,
weight and height [32].
Wilson and co-workers reported that MIP and MEP in
men were significantly correlated with age and weight,
whereas in women they were correlated with height and
weight, while Leech et al found that age had no consistent
effect on respiratory muscular strength [33,34].
Relationship between MEP and RV/TLC (p > 0.05; r2 = 0.01) Figure 6
Relationship between MEP and RV/TLC (p > 0.05; r2 = 0.01).Respiratory Research 2008, 9:8 http://respiratory-research.com/content/9/1/8
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In contrast with the study of Enright et al [35], our study
did not find any correlation with weight and age, proba-
bly because our patients had reached approximately 60
years of age with the same normal body weight.
For these reasons our study shows a significant linear rela-
tionship between respiratory muscles pressure and height.
This is likely to reflect an association between stature, dia-
phragm position and inspiratory muscle strength.
Nishimura showed that only lean body mass and abnor-
mal body weight were associated with decreased respira-
tory strength [18].
To conclude, when we treat a patient with severe airflow
obstruction we should consider the possible respiratory
muscle deterioration that could affect this sort of patients.
The periodical evaluation of the respiratory muscle
strength could represent a further and helpful tool in
monitoring the disease severity.
Our study is only a "snapshot" of the maximal respiratory
pressures and their correlation with functional parameters
at different stages of COPD severity in a hundred patients
living in Rome.
Further studies on a larger population sample are needed
to confirm our result.
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